Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Signoretti

Showing results (161-170 of 257) with videos related to

Pageof 26
Sort By:
Oncotarget|May 5, 2016
Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulationJianmin Wang, Antonios Papanicolau-Sengos, Sreenivasulu Chintala, et al.
Nature Genetics|June 4, 2013
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasionGuocan Wang, Andrea Lunardi, Jiangwen Zhang, et al.
Cancer Research|November 23, 2021
Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung CancerDeli Hong, Erik H Knelson, Yixiang Li, et al.
Cancer|April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge ConferenceMichael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2018
Autochthonous tumors driven by <i>Rb1</i> loss have an ongoing requirement for the RBP2 histone demethylaseSamuel K McBrayer, Benjamin A Olenchock, Gabriel J DiNatale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlatesToni K Choueiri, Susanna Jacobus, Joaquim Bellmunt, et al.
Molecular Cancer Research : MCR|February 2, 2022
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate CancerXueliang Gao, Yubao Wang, Caroline F Ribeiro, et al.
JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.
Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Cancer Immunology Research|November 24, 2020
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1Rupal S Bhatt, Abdulla Berjis, Julie C Konge, et al.
Pageof 26

Showing results (161-170 of 257) with videos related to

Sort By:
Pageof 26
Oncotarget|May 5, 2016
Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulationJianmin Wang, Antonios Papanicolau-Sengos, Sreenivasulu Chintala, et al.
Nature Genetics|June 4, 2013
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasionGuocan Wang, Andrea Lunardi, Jiangwen Zhang, et al.
Cancer Research|November 23, 2021
Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung CancerDeli Hong, Erik H Knelson, Yixiang Li, et al.
Cancer|April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge ConferenceMichael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2018
Autochthonous tumors driven by <i>Rb1</i> loss have an ongoing requirement for the RBP2 histone demethylaseSamuel K McBrayer, Benjamin A Olenchock, Gabriel J DiNatale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlatesToni K Choueiri, Susanna Jacobus, Joaquim Bellmunt, et al.
Molecular Cancer Research : MCR|February 2, 2022
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate CancerXueliang Gao, Yubao Wang, Caroline F Ribeiro, et al.
JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.
Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Cancer Immunology Research|November 24, 2020
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1Rupal S Bhatt, Abdulla Berjis, Julie C Konge, et al.
Pageof 26